NCT00170937View on ClinicalTrials.gov

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2006

Conditions
METABOLIC SYNDROMEHYPERTENSIONPRE-HYPERTENSION
Interventions
DRUG

valsartan plus hydrochlorothiazide

Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00170937 - A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome | Biotech Hunter | Biotech Hunter